Get the latest Science News and Discoveries
AACR: PARP1-selective inhibitor demonstrates early efficacy in breast cancers with DNA repair defects - EurekAlert
<p>The first-in-class PARP1-selective inhibitor saruparib demonstrated encouraging early efficacy and a favorable safety profile in patients with homologous recombination repair (HRR)-deficient breast cancers, according to results from the Phase I/II PETRA trial led by researchers at The University of Texas MD Anderson Cancer Center.</p>
None
Or read this on Eureka Alert